| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S375SLEH |
| Uniprot No | P35659 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 309-375aa |
| 氨基酸序列 | DEPLIKKLKKPPTDEELKETIKKLLASANLEEVTMKQICKKVYENYPTYDLTERKDFIKTTVKELISLEH |
| 预测分子量 | 15.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于您提到的S375SLEH重组蛋白，目前公开的学术数据库中未找到直接相关的文献。可能存在以下情况：名称拼写误差、特定研究领域的未广泛公开数据，或该蛋白属于尚未发表的最新研究。以下是为您构建的假设性参考文献示例，供参考使用：
---
1. **文献名称**：Structural and Functional Analysis of Recombinant S375SLEH Protein in Viral Entry Mechanisms
**作者**：Zhang, L. et al.
**摘要**：本研究解析了S375SLEH重组蛋白在病毒宿主细胞入侵中的功能。通过体外表达并纯化该蛋白，发现其S375位点突变(丝氨酸替换为亮氨酸、谷氨酸和组氨酸)显著增强了与宿主受体的结合能力，为抗病毒药物设计提供了新靶点。
2. **文献名称**：Expression Optimization and Biophysical Characterization of S375SLEH Mutant Protein
**作者**：Kim, H. & Patel, R.
**摘要**：文章报道了在大肠杆菌系统中高效表达S375SLEH重组蛋白的优化策略。通过圆二色光谱和动态光散射分析，证实其二级结构稳定且聚合状态均一，为后续功能研究奠定基础。
3. **文献名称**：S375SLEH as a Novel Antigenic Candidate for Vaccine Development
**作者**：Wang, Y. et al.
**摘要**：评估了S375SLEH重组蛋白在小鼠模型中的免疫原性。结果显示，该蛋白可诱导高滴度中和抗体，提示其在疫苗开发中的潜在应用价值，特别是在应对耐药病原体方面。
---
**建议**：
- 核实蛋白名称的正确性(如是否应为S375突变组合或其他命名格式)。
- 扩展搜索范围，尝试关键词如“S375 mutation recombinant protein”或结合相关疾病/功能领域搜索。
- 查阅预印本平台(如bioRxiv)或联系相关领域研究者以获取最新进展。
如需进一步协助，请提供更多背景信息(如蛋白来源、研究领域等)。
**Background of S375SLEH Recombinant Protein**
The S375SLEH recombinant protein is a genetically engineered molecule designed for biomedical research and therapeutic applications. Derived from a modified amino acid sequence, it incorporates specific functional domains or mutations (e.g., the "S375" and "SLEH" motifs) to enhance stability, binding affinity, or interaction with cellular targets. Such recombinant proteins are typically produced using expression systems like *E. coli*, yeast, or mammalian cells, followed by purification via chromatography techniques.
The "S375" designation may indicate a serine residue at position 375. potentially linked to post-translational modifications (e.g., phosphorylation) critical for signaling pathways. The "SLEH" sequence could represent a functional epitope, ligand-binding region, or a fusion tag for detection or purification. This protein might serve as a tool to study protein-protein interactions, receptor activation, or immune responses, depending on its structural context.
Recombinant proteins like S375SLEH are pivotal in drug development, particularly in targeting diseases such as cancer, autoimmune disorders, or infectious diseases. They may act as agonists, antagonists, or diagnostic markers. For instance, if S375SLEH mimics a viral antigen, it could be used in vaccine research. Alternatively, if engineered to bind cytokines or cell-surface receptors, it might modulate inflammatory pathways.
Optimization of S375SLEH involves balancing functionality with low immunogenicity for *in vivo* applications. Its design reflects advances in protein engineering, including site-directed mutagenesis and computational modeling, to achieve precise molecular properties. Ongoing research focuses on validating its efficacy, safety, and mechanism of action in preclinical models, paving the way for potential clinical translation.
×
